GNI Group Ltd.

2160.T
Biotechnology
2026/03/02 Updated
Market Cap: $1.1B (¥175.7B)
Stock Price: $20.22 (¥3,160)
Exchange Rate: 1 USD = ¥156.25

Stock Price Chart

2026/03/02 Updated
0.00
PER (Price Earnings Ratio)
vs Industry Avg: -9.6
3.51
PBR (Price to Book Ratio)
vs Industry Avg: +2.2
0.00%
Dividend Yield
vs Industry Avg: -2.95%

Price Trend

2026/03/02 Updated
Short-term
5-Day MA
+6.15%
Near-term
25-Day MA
+18.44%
Mid-term
75-Day MA
+25.02%
Long-term
200-Day MA
+14.20%

Price & Trading Details

2026/03/02 Updated

PRICE

Previous Close ¥3,015
Open ¥2,991
High ¥3,170
Low ¥2,989
Close ¥3,160

TRADING

Volume 1,277,200
Average Volume 1,434,658
Turnover ¥40億
Min. Purchase ¥316,000

Analyst Recommendations 3 analysts

Updated 2026/03/01
Strong Buy
0
Buy
3
3
Hold
0
Sell
0
Strong Sell
0
Target Price (Mean)
¥4,300
None
¥5,000
High
¥4,300
Median
¥3,600
Low
+73% vs Current Price
This information is based on market data from third-party data providers and is for reference only. Investment decisions are your own responsibility.

Shareholder Composition

Updated 2026/03/01
4.1%
Insider Holdings
9.8%
Institutional
86.2%
Public Float
40
Institutional Holders
Insider Holdings 4.1%
Institutional 9.8%
Public Float 86.2%

Financial Performance

2026/03/01 Updated

Revenue & Profit

Margins

Cash Flow

Financial Health

2021 2022 2023 2024
Income Statement
Revenue ¥12,690M ¥17,419M ¥26,011M ¥23,612M
Gross Profit ¥11,090M ¥14,745M ¥22,431M ¥18,037M
Operating Income ¥1,625M ¥1,378M ¥13,109M ¥1,402M
Pretax Income ¥1,755M ¥1,638M ¥13,863M ¥2,119M
Net Income ¥1,066M ¥389M ¥8,094M ¥1,098M
EPS ¥22.08 ¥8.11 ¥165.56 ¥21.15
Operating Margin 12.80% 7.91% 50.40% 5.94%
Balance Sheet
Total Assets ¥30,296M ¥33,907M ¥64,269M ¥71,943M
Total Equity ¥18,860M ¥20,970M ¥33,794M ¥36,446M
Total Liabilities ¥11,436M ¥12,937M ¥30,475M ¥35,497M
Cash ¥14,352M ¥11,049M ¥21,633M ¥10,115M
Interest-bearing Debt ¥1,126M ¥537M ¥3,699M ¥7,206M
Equity Ratio 62.25% 61.84% 52.58% 50.66%
D/E Ratio 0.06 0.03 0.11 0.20
Cash Flow
Operating CF ¥552M ¥393M ¥6,549M -¥3,164M
Investing CF -¥261M -¥4,116M -¥6,843M -¥10,361M
Financing CF ¥2,853M -¥646M ¥10,687M ¥694M
Free CF -¥142M -¥1,547M ¥4,473M -¥4,701M
Efficiency
ROE 5.65% 1.85% 23.95% 3.01%
ROA 3.52% 1.15% 12.59% 1.53%

Latest IR Information

Latest News (5 items)

Company Information

English Name GNI Group Ltd.
Japanese Name (株)ジーエヌアイグループ
Stock Code 2160.T (JPX)
Sector / Industry Healthcare / Biotechnology
Website https://www.gnipharma.com

About

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue-associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company is involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573, which is in phase II for the treatment of acute chronic liver failure. Further, it is developing F528, which is in Phase 2 clinical trial for Chronic Obstructive Pulmonary Disease; and F230, which is in clinical trial for Pulmonary Arterial Hypertension. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.

Data provided by Yahoo Finance